Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac372
Abstract: Abstract Background The M2 metabolite of bedaquiline causes QT-interval prolongation, making electrocardiogram (ECG) monitoring of patients receiving bedaquiline for drug-resistant tuberculosis necessary. The objective of this study was to determine the relationship between M2 exposure… read more here.
Keywords: ecg monitoring; qtcf; monitoring strategies; monitoring ... See more keywords
Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/13993003.00738-2017
Abstract: 5 years after its first approval by a stringent regulatory authority, the role of bedaquiline in the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) is well established, and acknowledged by existing guidance.… read more here.
Keywords: bedaquiline; bedaquiline treatment; treatment multidrug; resistant tuberculosis ... See more keywords
Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV
Sign Up to like & getrecommendations! Published in 2021 at "Emerging Infectious Diseases"
DOI: 10.3201/eid2703.202359
Abstract: Nontuberculous mycobacteria can cause disseminated infections in immunocompromised patients and are challenging to treat because of antimicrobial resistance and adverse effects of prolonged multidrug treatment. We report successful treatment with bedaquiline, a novel antimycobacterial drug,… read more here.
Keywords: disseminated nontuberculous; nontuberculous mycobacteria; treatment disseminated; treatment ... See more keywords